Other advanced dual SRC-ABL inhibitors include FB2, a N-(thiazol-2-yl)pyrimidin-4-amine derivative (structure not completely disclosed) which shows in vitro and in vivo activity against TKI-resistant CML cell lines [109,110], and bafetinib (INNO-406, NS-187; Figure 6), an orally available inhibitor with activity on a number of ABL mutations which also selectively inhibits Lyn over other SRC family members and is able to penetrate the central nervous system (CNS) in murine models [111,112]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.